BioCentury
ARTICLE | Clinical News

Norovirus VLP vaccine: Phase I data

May 17, 2010 7:00 AM UTC

Data from the double-blind, dose-escalation, U.S. Phase I LV01-101 trial in 28 healthy volunteers ages 18-49 showed that 5, 15 and 50 µg doses of intranasal Norovirus VLP vaccine produced seroconversi...